Drug-Drug-Gene Interactions and Adverse Drug Reactions
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (1 March 2024) | Viewed by 183
Special Issue Editor
Interests: gender pharmacology; gender medicine; pharmacokinetics; pharmacogenomics; personalized therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Drug–drug–gene interactions happen when genetic and concomitant drugs interfere with treatment pharmacokinetics and/or pharmacodynamics. Inhibitory, inducing, and phenoconversion interactions between drugs and genes are possible. Any interactions that alter the pharmacokinetics of the victim drugs to either raise or lower the drug concentrations are referred to as inducing or inhibiting interactions. Induction or inhibition can be caused by the administration of another drug that changes the metabolism or transport of the victim drug due to the presence of loss- or gain-of-function genetic variants that change the functions of enzymes.
The Special Issue will focus on drug–drug–gene inhibitory interactions, induction interactions, and phenoconversion interactions. This Special Issue is open to experimental studies, clinical research, and reviews which highlight drug–drug–gene interactions’ possible role in clinical practice.
Dr. Sarah Allegra
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacokinetics
- pharmacodynamics
- pharmacology
- adverse drug reaction
- drug-drug-gene interaction
